American Diabetes Association
Browse
DOCUMENT
cd23-0057_Supplementary_Material--Figures.pdf (128.84 kB)
DOCUMENT
cd23-0057_Supplementary_Material--Focus_Group_Guide_FINAL.pdf (135.69 kB)
DOCUMENT
cd23-0057_Supplementary_Material--Table_S1.pdf (148.01 kB)
1/0
3 files

Understanding Providers’ Readiness and Attitudes Toward Autoantibody Screening: A Mixed-Methods Study

figure
posted on 2023-10-12, 18:35 authored by Emma Ospelt, Holly Hardison, Nicole Rioles, Nudrat Noor, Ruth S. Weinstock, Kristina Cossen, Priyanka Mathias, Allison Smego, Nestoras Mathioudakis, Osagie Ebekozien, \\the T1D Exchange Quality Improvement Collaborative

Screening for autoantibodies associated with type 1 diabetes can identify people most at risk for progressing to clinical type 1 diabetes and can provide an opportunity for early intervention. Drawbacks and barriers to screening exist, and concerns arise, as methods for disease prevention are limited and no cure exists today. The availability of novel treatment options such as teplizumab to delay progression to clinical type 1 diabetes in high-risk individuals has led to the reassessment of screening programs. This study explored awareness, readiness, and attitudes of endocrinology providers toward type 1 diabetes autoantibody screening.

Funding

Leona M. and Harry B. Helmsley Charitable Trust

History

Usage metrics

    Clinical Diabetes

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC